Decoy 20
Alternative Names: Decoy-20; INDP-020Latest Information Update: 28 Jun 2025
At a glance
- Originator Decoy Biosystems
- Developer Indaptus Therapeutics
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
- No development reported Lymphoma
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Lymphoma in USA (IV)
- 02 Apr 2025 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05651022)
- 20 Mar 2025 Updated pharmacodynamics and adverse events data from a phase I trial in Solid tumour released by Indaptus Therapeutics